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ABSTRACT. Modifications in the GABA pathway are considered 
to be responsible for motor alterations in animal models for fragile 
X-associated tremor ataxia syndrome. We analyzed the expression 
profile in the cerebellum in a transgenic mouse model that over expresses 
the human FMR1 gene with CGG repeats in the normal range. We used 
the “GeneChip Mouse Gene 1.0 ST Array” from Affymetrix analyzing 
28,853 well-described and -characterized genes. Based on data from the 
comparative analysis of the expression profile, we detected a significant 
gradient with a P value <0.1 and changes in expression equal to or 
greater than 1.5 times compared to the control mouse genes. There were 
significant changes in the expression of 104 genes, among which 72% 
had decreased and 28% had increased expression. With the exception 
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of GabarapL2, no changes in expression of genes from the GABA 
pathway were observed, which may explain the absence of an altered 
motor phenotype in these mice. These results further support the view 
that toxic effects in fragile X-associated tremor ataxia syndrome are 
due to expansion of CGG repeats rather than increased mRNA levels, 
since in the transgenic mice the FMR1 mRNA levels were increased 
20-100 times compared with those of control littermates.
Key words: Animal model; Microarrays; FMR1; Cerebellum; FXTAS 
INTRODUCTION
Loss of expression of the FMR1 gene by increased CGG trinucleotide repeats (<200) 
in the 5'UTR causes the most frequent inherited form of mental retardation (fragile X syn-
drome, FXS), whereas carriers of premutation alleles (55-200 CGG triplet repeats) may 
present a specific late-onset neurodegenerative disorder characterized by tremor, ataxia, par-
kinsonism, and intellectual decline (fragile X-associated tremor ataxia syndrome, FXTAS) 
(Hagerman et al., 2001; Hagerman and Hagerman, 2004a; Jacquemont et al., 2007; Costa et 
al., 2011; Greco et al., 2011). Neurohistological studies on the brain of premutation carriers 
have demonstrated neuronal degeneration in the cerebellum and the presence of eosinophilic 
intranuclear inclusions in both neurons and astroglia (Jacquemont et al., 2003; Greco et al., 
2006; Wenzel et al., 2010).
The increase in CGG repeats is parallel to an increase in FMR1 mRNA levels without 
significant changes in FMR1 mRNA stability (Kenneson et al., 2001; Loesch et al., 2007; 
Tassone et al., 2007). The knock-in mouse model generated in which the endogenous CGG 
repeat was replaced by a human CGG repeat in the premutation range displays biochemical, 
phenotypic and neuropathological characteristics of FXTAS (Willemsen et al., 2003). As in 
humans, the expanded CGG repeat mouse model shows elevated fmr1 mRNA levels in the 
brain compared with controls (Willemsen et al., 2003; Brouwer et al., 2007; Hunsaker, 2011). 
The elevated level of this abnormal mRNA is believed to be the cause of the neurodegenera-
tive disorder. In a Drosophila model expressing a portion of the premutated human FMR1 
5'UTR the repeats may cause neurodegeneration in a dosage- and repeat length-dependent 
manner (Jin et al., 2003). An almost normal CGG repeat of 60 triplets, when moderately ex-
pressed, has little phenotype, and this same allele, when overexpressed, does lead to neurode-
generation, supporting the notion that overall rCGG abundance is critical for the pathological 
phenotype (Jin et al., 2003). The toxicity of the FMR1 mRNA has been related to the excess 
recruitment of one or more RNA-binding proteins to the expanded repeats causing depletion 
and loss of function of these proteins (Hagerman and Hagerman, 2004b, 2007). Dysfunction in 
RNA metabolism has also been involved in the pathogenesis of several neurological disorders 
(Ginsberg et al. 1998; Gallo et al., 2005; Oostra and Willemsen, 2009; Lemmens et al., 2010).
It has been reported that overexpression of the FMR1 gene with CGG in the normal 
range does not rescue the fragile X phenotype in KO mouse (Bakker et al., 2000) although a 
reversal of sensomotor gating abnormalities in the KO mice carrying a human FMR1 trans-
gene has been described (Paylor et al., 2008). However, a more detailed study of transgenic 
mice without CGG expansion is missing. To ascertain whether an increase in the FMR1 mes-
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senger level, independently of the CGG number, may affect the expression profile in cerebel-
lum we performed a microarray analysis from a transgenic mouse model that overexpresses 
(20-100-fold) the human FMR1 gene with CGG in the normal range.
MATERIAL AND METHODS
Animal models
The experiments were conducted in accordance with institutional guidelines and ap-
proved by the Animal Ethics Committee of the University of Seville. We generated a trans-
genic line that overexpresses human FMR1 with CGG in the normal range (29 repeats). An 
EcoRI fragment containing the human FMR1 cDNA kindly supplied by Dr. Verker (Erasmus 
Medical Center, Rotterdam, The Netherlands) was cloned in the EcoRI site of the expression 
vector pSG5. The plasmid plus the FMR1 cDNA was grown in an LB broth buffer and the 
construction was cut with SalI restriction enzyme. SalI generates two fragments, one of 4.56 
kb corresponding to the FMR1 gene, T7 promoter, the β-globin intron and SV40 promoter and 
a fragment of 3.04 kb from the rest of the plasmid (Figure 1A).
The 4.56-kb fragment containing the FMR1 cDNA was extracted from 0.8% agarose 
gel and purified with a kit from Qiagen (Qiagen Iberia, Madrid, Spain) (Figure 1B). A solution 
of 2.5 ng/µL containing the purified 4.56-kb fragment was microinjected into the pronucleus 
of fertilized murine oocytes as previously described (Mejias et al., 2006) and we selected two 
founder lines. DNA was extracted from mouse tissue by the QuickExtractTM DNA Extraction 
Solution 1.0 (Epicentric, Biotechnologies, Madison, WI, USA) and tested by conventional 
PCR of the KH domains with primers between exons 7 and 11 to prevent genomic DNA am-
plification as previously described (Hmadcha et al., 1998). The PCR was productive only in 
animals where the insert was incorporated in their genome (Figure 1C).
RNA extraction and quantitative RT-PCR
Cortex, cerebellum and liver tissues of transgenic mice and control littermates were 
dissected, placed immediately in TRIsure buffer and RNA was extracted as indicated by the 
manufacturer (Bioline, Luckenwalde, Germany). The concentration and quality of total RNA 
were analyzed spectrophotometrically. RNA was stored at -80°C until used. Reverse transcrip-
tion (RT) reaction was performed in 40 µL with 0.5 to 1 µg total RNA, 1X PCR buffer, 5.5 
mM MgCl2, 1 mM each dNTP, 5 µM random primers, 0.4 RNAse inhibitor and 2.5 U M-MLV 
reverse transcriptase (Promega, Madison, WI, USA).
Quantitative (fluorescence) RT-PCR was performed in an ABI Prism 7300 Real-Time 
PCR System (Applied Biosystems, USA). PCRs were performed in triplicate in a total volume 
of 25 µL containing 100 ng cDNA and the SensiMix SYBR Green PCR master mix following 
the conditions recommended by the manufacturer (Quatance, London, UK). Primer sequenc-
es for human FMR1 were from exon 3 and exon 5, FMR201F: 5'-GCAGATTCCATTTCAT 
GATGTCA-3', and FMR327R: 5'-CAATTGTGACAATTTCATTGTAAGTT-3' as described 
by Allen et al. (2004). For internal control, we used hprt gene expression assessed by us-
ing murine primers: hprtF: 5'-CACAGGACTAGAACACCTGC-3' and hprtR: 5'-GCTGGT 
GAAAAGGACCTCT-3' as described by Drabek et al. (1997).
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Quantitative RT-PCR amplification of c-fos was also performed in the ABI 7300 
Real-time PCR System with gene-specific primers using the following sequences: fosF: 
5'-CTGTCAACACACAGGACTTTT-3' and fosR: 5'-AGGAGATAGCTGCTCTACTTTG-3'. 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal control, 
and was amplified using the following primers: GAPDH-F: 5'-CTTCACCACCATGGAGA 
AGGC-3' and GAPDH-R: 5'-GGCATGGACTGTGGTTCAT-3' as described by Janitzky et al. 
(2009). For all genes analyzed by quantitative RT-PCR the thermal cycle conditions consisted 
of initial denaturation at 95°C for 10 min followed by 40 cycles of 15 s at 95°C and 1 min 
at 60°C. Melting curve analysis showed a single sharp peak with the expected Tm for all 
samples. Determinations of cycle threshold were performed automatically by the instrument 
and calculations were done as described by Tassone et al. (2000a).
Figure 1. A. Scheme of the plasmid used to obtain the transgenic mice. The characteristics of the pSG5 plasmid 
are shown. The plasmid is cut with EcoRI where the cDNA of the human FMR1 (3.5 kb) was inserted. The 
construct was incorporated into competent cells and grown in a medium with ampicillin. B. Plasmid extraction 
and digestion with SalI. The plasmid was extracted with a kit from Quiagen and digested with the restriction 
enzyme SalI. Two fragments of 4.561 and 3.039 kb were obtained. The 4.561-kb fragment contains FMR1 cDNA, 
SV40 promoter and beta-globin intron. This fragment was separated on 0.8% agarose gel and purified. Dilutions 
were made for the injection in fertilized ovocites. Lane ND = plasmid non-digested; lane D = plasmid digested 
with SalI. C. Detection of transgenic mice. Two founder lines were obtained (lines A and B). Genotyping was 
performed by conventional PCR of the KH domains and yielded a 500-bp fragment. Only animals that have 
incorporated the FMR1 gene amplified the 500-bp fragment. Groups of both positive (+/-) and negative (-/-) mice 
of the same line and age were selected for the experiments. Lanes 1, 2, 3, 4, 6, 8, 10, 13, 15, 16, 17, and 18 = 
negative mice; lanes 5, 7, 9, 11, 12, and 14 = positive mice; lane 19 = a positive control.
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Microarray analysis
For microarray experiments RNA from transgenic mice and control littermates was 
extracted and maintained at 80°C until used. Gene expression profile was determined by us-
ing a “GeneChip Mouse Gene 1.0 ST Array” by Affymetrix platform at the Genomics Unit 
of CABIMER (Seville, Spain) containing 28,853 well-described and characterized genes. 
Quality of total RNA from mice was confirmed with Bioanalyzer® 2100 (Agilent technol-
ogy). Synthesis, labeling and hybridization were performed with RNA from three independent 
mice of each condition following Affymetrix recommended protocols. Probe signal intensities 
were captured and processed with the GeneChip® Operating Software 1.4.0.036 (Affymetrix), 
and the resulting CEL files were reprocessed using robust multi-array average normalization 
(Irizarry et al., 2003). Fold change (log2) values and their P values were calculated with linear 
models for microarray analysis (Smyth, 2004), using the oneChannelGUI interface (Sanges et 
al., 2007). All statistical analyses were performed using R language and the packages freely 
available from the “Bioconductor Project” (http://www.bioconductor.org). With the data re-
sulting from the comparative analysis of the expression profile, we established a significant 
grade with P value <0.1 and linear fold change in expression equal to or above 1.5 times above 
the control mouse. The functional annotation was analyzed using the DAVID Bioinformatics 
Database (http://david.abcc.ncifcrf.gov/home.jsp). The association of differentially expressed 
genes with genetic disorders and neurological diseases as well as hepatic diseases was identi-
fied using the IPA 9.0 software (Ingenuity Systems, www.ingenuity.com) available through 
the PAB (The Andalusian Platform of Bioinformatics www.scbi.uma.es) from the University 
of Malaga.
Assessment of exploration and activity
Open-field behavior was recorded in a brightly lit 50 x 50-cm arena. Mice always 
started from the center of the arena and were allowed 1 min of adaptation before the 60-min 
recording period commenced. A computerized video-tracking system (Smart.V2.5, Panlab, 
Barcelona, Spain) was used to record trajectories and calculate path length and time spent in 
the square periphery of the arena (Van Dam, 2005). 
Statistical analysis
Exploration and activity data are presented as means ± SD, with the number (N) of ex-
periments indicated. The statistical analysis of the data was performed using a non-parametric 
test. In particular, the Mann-Whitney U-test was used to check for statistical differences in 
distance covered and time spent in the periphery of the arena (PT%) between the control and 
the transgenic group. P values smaller than 0.1 were considered to be statistically significant.
RESULTS
We used the pronuclear injection of the 4.56-kb fragment to generate a transgenic 
mouse model that overexpresses human FMR1 with CGG trinucleotide repeats in the normal 
range (29 repeats). Animals were genotyped by conventional PCR of the KH domain as in-
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dicated in Material and Methods (see Figure 1C). Two founder lines, A and B, were obtained 
and positive (+/-) and negative (-/-) animals of the same age were maintained to perform the 
experiments.
Quantitative RT-PCR showed that the relative FMR1 mRNA level in all tissues ana-
lyzed from transgenic mice was much higher than in the wild type. Figure 2 shows in bar 
diagrams the mean of three different experiments of FMR1 mRNA levels in cerebellum, cor-
tex and liver from mice at 14 weeks of age from line B. FMR1 mRNA in the cerebellum of 
transgenic mice was 20 times higher than in the wild type, and the expression in cortex and 
liver tissue of transgenic mice was even higher compared to controls (50-100 times).
Figure 2. Quantitative RT-PCR of mFMR1 in transgenic mice. Cerebellum (Cr), liver tissue (L) and cortex (Co) 
were dissected from transgenic and wild-type mice. RNA was isolated and reverse transcribed as indicated in 
Material and Methods. Real-time PCR showed that the expression of human FMR1 was 20 to 100 times (fold 
change) higher than the values in control littermates, which were normalized to one (C). The results are reported as 
means ± SD of three different experiments from line B.
Behavioral analysis of male mice at 7 and 14 months did not show statistically signifi-
cant differences between transgenic mice and control littermates (Table 1). The animals did not 
reveal significant differences in general activity or anxiety-related behaviors in the open-field 
test. Similar results were obtained using female mice of 3 and 11 months (data not shown).
 Wild type  Transgenic
 Distance PT% Distance PT%
7 months 13883 ± 5377 (6) 13.57 ± 5.7 (6) 12187 ± 2561 (6) 16.04 ± 7.43 (6)
14 months 11923 ± 4777 (4)     23.2 ± 4.73 (4) 11928 ± 2770 (4)   15.79 ± 11.18 (4)
Distance covered is reported in cm and permanence time (PT%) in percent of the total time spent in the periphery 
of the arena. Data are reported as means ± SD. Number of animals analyzed is indicated in parentheses.
Table 1. Assessment of exploration and activity.
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For microarray analysis, we used transgenic mice of 20 weeks of age and control 
littermates. Considering the significant grade and linear changes in expression indicated in 
Material and Methods, we observed changes in 75 well-described genes in which 70% are 
inhibited and 30% increased by FMR1 overexpression. Following the data supported by IPA 
9.0 (see Material and Methods), we divided the changed genes into four categories including 
those related to neurological diseases and the GABAergic signaling pathway (Figure 3).
Table 2 shows a detailed description of the 35 genes corresponding to the groups of 
neurological diseases (blue columns in Figure 3) and genetic disorders (green columns in Fig-
ure 3). A Veen diagram shows the genes shared by both groups and a subset of genes involved 
also in hepatic diseases.
The most affected gene is transthyretin (Ttr), a carrier of thyroxine and retinol that 
decreases four times compared with controls. On the other hand, Serpina3, a serine proteinase 
inhibitor (α-1-antichymotrypsin), is the most up-regulated gene from the neurological disease 
group. The data show that with the exception of the up-regulation of GabarapL2 no change in 
expression of genes from the GABAergic pathway was observed. We have confirmed by real-
time PCR the up regulation of cfos obtained in the microarray experiments (data not shown).
Figure 3. Gene expression profile in the cerebellum from transgenic mice. Cerebellar tissue was dissected and RNA 
was extracted as described in Material and Methods. cDNA was obtained by reverse transcription and expression 
was analyzed by “GeneChip Mouse ST 1.0 Array” manufactured by Affymetrix. The diagram shows the 75 well-
characterized genes that present changes equal to or above 1.5 times with respect to control littermates and with 
a P value <0.1. From these genes 70% were inhibited (down in the graphic) and 30% were increased (up in the 
graphic). Genes related to neurological diseases are represented in blue, genes related to known genetic disorder 
in green and, other misregulated genes in yellow. With the exception of GabarapL2 (red column) no known gene 
from the GABAergic pathway was altered.
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These results indicate that the increase in the expression of human FMR1 mRNA with 
CGG triplets in the normal range in mice produced mild changes in the transcriptome but did 
not affect the GABAergic pathway or induce the motor alterations described in the animal 
model of FXTAS. The possible significance of the altered gene expression profile in the trans-
genic mice reported here should be further analyzed.
DISCUSSION
The involvement of the GABAergic system in both FXS and FXTAS, the two faces 
of the FMR1 gene, has been reported (D’Hulst et al., 2009). Expression analysis of fmr1 KO 
mice compared to wild type shows decreased expression of several subunits of the GABAA 
receptor in fragile X mouse cortex, but not in cerebellum. By contrast overexpression of sev-
eral GABAA receptor subunits and proteins involved in GABA metabolism has been observed 
in cerebellum but not in the cortex of the mice model for FXTAS (D’Hulst et al., 2009). This 
is consistent with the cerebellar phenotype of FXTAS patients (D’Hulst et al., 2009) although 
the precise mechanistic relationship between CGG size and clinical phenotype is still unclear. 
It is likely that a combination of CGG repeat length and FMR1 message abundance together 
may define a threshold for the clinical manifestation of the disease (Jin et al., 2003; Willemsen 
et al., 2003; Brouwer et al., 2007). In our transgenic mice expression of human FMR1 mRNA 
is 20 to 100 times higher than in controls in any tissue analyzed (see Figure 2). These levels 
are an order of magnitude higher than the 2-6-fold elevated FMR1 mRNA levels found in 
Venn diagram. Intersection of genes from different groups. The criteria used to define candidate differentially 
expressed genes are indicated in Material and Methods. Genes from “Other misregulted” group (yellow columns 
in Figure 3) are not described.
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premutation carriers or in the transgenic CGG-expanded repeat mouse model (Tassone et al., 
2000a; Willemsen et al., 2003).
The high expression of human FMR1 mRNA results in a differential expression pat-
tern in cerebellum but only the GabarapL2 gene from the GABAergic pathway was changed. 
According to these results, we did not find any motor phenotype in males or females at differ-
ent ages (see Table 1). These data agree with the absence of correlation between Fmr1 mRNA 
levels and neuropathological features found in the CGG-repeat knock-in mouse model (Brou-
wer et al., 2008). This study further supports the view that gain-of-function in FXTAS arises 
as a result of the expanded CGG repeats rather than the abnormally increased levels of FMR1 
mRNA present in a carrier of premutation alleles. Therefore, it would be of interest to know if 
fragile X males with unmethylayed full-mutation trinucleotide repeat expansions (Tassone et 
al., 2000b) show a severe form of FXTAS or an early presentation due to the very large CGG 
repeat expansion.
Interestingly, the two most altered genes from the group of neurological diseases, Trt 
and Serpina 3, found in our transgenic mice, are related to Alzheimer disease. A decrease in 
TRT has been associated with late onset Alzheimer disease and it is used in cerebrospinal fluid 
as a bio-marker (Buxbaum et al., 2008). On the other hand, up-regulation of Serpina 3 is found 
in Alzheimer patients (Porcellini et al., 2008). Thus, this may suggest an RNA toxicity that 
would work through alteration of specific genes. A subgroup of modified gene expression is 
related to hepatic diseases (see Venn diagram and Table 2). Since the transgenic mice reported 
here express extremely high FMR1 mRNA levels in liver it would be of interest to know the 
gene expression profile of this tissue and its correlation with a possible hepatic phenotype.
The increase in c-fos proto-oncogene observed in the microarray has been validated 
by quantitative RT-PCR. However, Fmr1 mRNA was not changed in the microarray analysis 
due to specific amplification of mouse Fmr1 without recognition of human FMR1 cDNA.
In conclusion, differential expression of genes determined by microarray analysis 
from transgenic mice versus wild type did not induce changes in the GABAergic system and 
transgenic mice did not show a cerebellar phenotype. The changes in the transcriptome may 
produce a non-cerebellar phenotype that should be further investigated.
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